Index

Note: Page numbers of article titles are in boldface type.

A

Acquired acute fulminating myasthenia gravis, 1216–1218
  clinical signs of, 1216–1217
  diagnosis of, 1217
  introduction, 1216
  prognosis of, 1217–1218
  treatment of, 1217–1218
Acute idiopathic polyradiculoneuritis (AIP), 1202–1208
  clinical signs of, 1203–1204
  diagnosis of, 1204–1205
  introduction, 1202–1203
  pathophysiology of, 1203
  prognosis of, 1205–1208
  treatment of, 1205–1208
Acute lower motor neuron (LMN) tetraparesis, 1201–1222. See also specific types, e.g., Botulism
  acquired acute fulminating myasthenia gravis, 1216–1218
  AIP, 1202–1208
  botulism, 1208–1213
  introduction, 1201–1202
  tick paralysis, 1213–1216
Acute repetitive seizures (ARS)
  defined, 1104
Acute spinal cord injury (SCI), 1131–1156. See also Spinal cord injury (SCI), acute
Adoptive immunotherapy
  in brain tumor management
    in dogs and cats, 1028–1029
Age
  as factor in prognosis after SCI, 1147
Aging
  in canine brain, 1113–1129
    clinical implications of, 1121–1122
    introduction, 1113–1114
    lysosomal storage diseases, 1118–1119
    neurobiology of, 1114–1119
      brain atrophy, 1114–1115
      selective neuron loss, 1115
      senile plaques, 1115–1116
      vascular disorders, CAA, 1116–1117
    oxidative damage and mitochondrial dysfunction, 1118
    tau neuropathology of, 1117
  in feline brain, 1113–1129
Aging (continued)
  clinical implications of, 1121–1122
  introduction, 1113–1114
  neurobiology of, 1119–1121
    Aβ, 1119–1120
    neuron loss and atrophy, 1119
    neuronal loss in NPC disease, 1120–1121
    tau phosphorylation, 1120
AIP. See Acute idiopathic polyradiculoneuritis (AIP)
Altered states of consciousness
  in small animals, 1039–1058. See also Consciousness, altered states of
ARS. See Acute repetitive seizures (ARS)
Ataxia(s)
  hereditary
    canine, 1075–1089. See also Hereditary ataxia(s), canine

B
Bacteria
  in infectious CNS disease
    testing for, 1194–1195
Biomarker(s)
  for neural injury and infection in small animals, 1187–1199. See also Neural injury,
    biomarkers for
      in prognosis after SCI, 1148
Blood pressure
  abnormalities in
    after SCI
      in dogs, 1137
Border Terriers
  epileptoid cramping in, 1098
Botulism, 1208–1213
  clinical signs of, 1211
  diagnosis of, 1212
  introduction, 1208–1210
  pathophysiology of, 1210
  prevention of, 1213
  prognosis of, 1212–1213
  treatment of, 1212–1213
Boxers
  paroxysmal dyskinesia in, 1099
Brain
  aging of
    in canine and feline brain, 1113–1129. See also Aging, in canine brain; Aging,
      in feline brain
Brain biopsy
  in MUO evaluation, 1171
Brain tumors
  treatment of
    in dogs and cats, 1013–1038. See also specific methods, e.g., Stereotactic radiosurgery
CED, 1020–1026. See also Convection-enhanced delivery (CED)
current options, 1014–1015
immunotherapy, 1026–1031. See also Immunotherapy
introduction, 1013–1015
stereotactic radiosurgery, 1015–1020

C
CAA. See Cerebrovascular amyloid angiopathy (CAA)
Candidate gene analysis
   in identifying underlying cause of inherited neurologic disorders in dogs, 1228
Canine multiple system degeneration (CMSD), 1085–1086
Carbon dioxide
   oxygen and
      in altered states of consciousness management, 1052–1054
Cat(s)
   brain of
      aging effects on, 1113–1129. See also Aging, in feline brain
   brain tumors in
      treatment of, 1013–1038. See also Brain tumors, treatment of, in dogs and cats
   experimental models with SCI
      cell transplantation in, 1144–1145
   intervertebral disk disease in
      as factor in prognosis after SCI, 1147–1148
   SE in
      treatment of, 1107
Cavalier King Charles spaniels
   episodic falling in, 1093–1095
CED. See Convection-enhanced delivery (CED)
Cell transplantation
   in acute SCI management
      evidence for, 1142–1144
   in clinical cases with SCI, 1145
   in experimental models of SCI
      canine, 1144
      feline, 1144–1145
Central nervous system (CNS) disease
   immune-mediated
      neuroinflammation and, 1159–1161
   infectious
      testing for, 1193–1196
      introduction, 1193
      microbial agent–related, 1194–1196
      PCR–based techniques, 1193–1194
      limitations of, 1194
   noninfectious inflammatory
categorization of, 1158
Central nervous system (CNS) neoplasia
   glucocorticoids for, 1065
Cerebellar cortical degeneration
   canine, 1080–1083
Cerebellar (continued)
   mapped diseases, 1083
   RAB24, 1083
   SEL1 mutation, 1082
   SPTBN2, 1083
Cerebrospinal fluid (CSF) analysis
   in MUO evaluation, 1171
Cerebrospinal fluid (CSF) production
   reduction in
e   corticosteroid use and
      in small animal neurology, 1062
Cerebrovascular amyloid angiopathy (CAA)
   in canine brain
   aging and, 1117–1118
Chinooks
   PNKD in, 1095
Cleaved tau
   for neural injury and infection in small animals, 1191
Cluster seizures
   defined, 1104
   treatment of, 1109
CMSD. See Canine multiple system degeneration (CMSD)
CNS. See Central nervous system (CNS)
Consciousness
   altered states of
      in small animals, 1039–1058
         coma scales in
            future uses, 1056
            described, 1040–1041
            diagnostic approach to, 1049–1052
               electrodiagnostic evaluation, 1051–1052
               laboratory and ancillary investigations, 1049
               neuroimaging, 1049–1051
            immediate emergency treatment for, 1052–1055
               diuretics, 1055
               fluid therapy, 1054–1055
               general care, 1052
               oxygen and carbon dioxide management, 1052–1054
            introduction, 1039–1040
            neurologic evaluation of, 1043–1049
            prognosis of, 1056
   impaired
      in small animals, 1040–1041. See also Consciousness, altered states of, in small animals
      neuro-anatomical basis of, 1041–1042
Convection-enhanced delivery (CED)
   in brain tumor management
      in dogs and cats, 1020–1026
         infusion techniques, 1024–1026
      introduction, 1020–1021
procedure, 1021–1022
technical factors governing insulate distributions in brain, 1022–1024

Corticosteroid(s)
in small animal neurology, 1059–1074
detrimental effects of, 1068–1069
glucocorticoids for specific conditions, 1063–1068. See also Glucocorticoid(s), in small animal neurology
introduction, 1059–1060
mechanisms of activity, 1060–1063
activity via nongenomic effects, 1061
activity via nuclear effects, 1060–1061
immune system effects, 1062–1063
metabolic effects, 1061–1062
blood pressure effects, 1062
CSF production reduction, 1062
 gluconeogenic effects, 1061
therapeutic effects of glucocorticoids, 1061

CSF. See Cerebrospinal fluid (CSF)
Cutaneous trunci muscle reflex
as factor in prognosis after SCI, 1147
CyberKnife stereotactic radiosurgery
in brain tumor management
in dogs and cats, 1017–1018

Cytokine immunomodulation
in brain tumor management
in dogs and cats, 1027

D

Diarrhea
corticosteroid therapy and, 1068

Diuretics
in altered states of consciousness management, 1055

DNA testing
in inherited neurologic disorders in dogs, 1231–1233

Dog(s)
blood pressure abnormalities in
after SCI, 1137
brain of
ageing effects on, 1113–1129. See also Aging, in canine brain
brain tumors in
treatment of, 1013–1038. See also Brain tumors, treatment of, in dogs and cats
experimental models with SCI
cell transplantation in, 1144
hereditary ataxia in, 1075–1089. See also Hereditary ataxia(s), canine
inherited neurologic disorders in, 1223–1234. See also Neurologic disorders, inherited, canine
paroxysmal movement disorders in, 1091–1102. See also Movement disorders, paroxysmal, canine
SE in, 1107–1109
Dyskinesia(s)
paroxysmal. See Paroxysmal dyskinesia phenobarbital-induced, 1100

E
Encephalitis
necrotizing
signalment, neurologic signs, and histopathologic features of, 1166–1168
Epileptoid cramping
in Border Terriers, 1098
Episodic ataxia
canine, 1086
Episodic head tremor syndrome
canine, 1098–1099

F
Fluid therapy
in altered states of consciousness management
in small animals, 1054–1055
Focal seizure
defined, 1104
Fosphenytoin
for SE in dogs, 1109
Fungus(i)
in infectious CNS disease
testing for, 1196

G
Gamma Knife stereotactic radiosurgery
in brain tumor management
in dogs and cats, 1016–1017
Generalized seizure
defined, 1103
Genetic linkage analysis
in identifying underlying cause of inherited neurologic disorders in dogs, 1226
Genetic markers
in identifying underlying cause of inherited neurologic disorders in dogs, 1225–1226
Genetic testing
in MUO evaluation, 1172
Genome-wide association studies (GWAS)
in identifying underlying cause of inherited neurologic disorders in dogs, 1226–1227
GFAP. See Glial fibrillary acidic protein (GFAP)
Glasgow Coma Scale
modified
in neurologic evaluation of impaired consciousness, 1043–1049
Glial fibrillary acidic protein (GFAP)
for neural injury and infection in small animals, 1190–1191
Glucocorticoid(s)
in small animal neurology
for CNS neoplasia, 1065
contraindications to, 1067–1068
for corticosteroid-responsive meningitis, 1063
for immune-mediated disease, 1063
for immune-mediated myositis, 1064–1065
for infectious disease, 1066
for MUO, 1064
for myasthenia gravis, 1065–1066
for pain control, 1066–1067
for polyradiculoneuritis, 1065–1066
therapeutic effects of, 1061
Granulomatous meningoencephalomyelitis
    signalment, neurologic signs, and histopathologic features of, 1163–1166
Growth factors
    for neural injury and infection in small animals, 1192
Gut ulceration
    corticosteroid therapy and, 1068
GWAS. See Genome-wide association studies (GWAS)

H
Hereditary ataxia(s)
canine, 1075–1089
    cerebellar cortical degeneration, 1080–1083
classification of, 1076–1077
clinical approach to, 1077–1080
CMSD, 1085–1086
episodic, 1086
introduction, 1075
spinocerebellar degeneration, 1083–1085
without neurodegeneration, 1085

I
Immune-mediated CNS disease
glucocorticoids for, 1063
neuroinflammation and, 1159–1161
Immune system
corticosteroid use effects on
    in small animals, 1062–1063
Immunosuppression
corticosteroid therapy and, 1068
Immunotherapy
    in brain tumor management
        in dogs and cats, 1026–1031
            active immunotherapy, 1029–1030
            adoptive immunotherapy, 1028–1029
            cytokine immunomodulation, 1027
        future directions in, 1030–1031
history/rationale, 1027
introduction, 1026
Index 1255
Immunotherapy (continued)
   monoclonal antibodies, 1027–1028
   passive immunotherapy, 1027–1029
   strategies, 1027–1030
Infectious disease(s)
   CNS
      testing for, 1193–1196. See also Central nervous system (CNS) disease, infectious, testing for
   glucocorticoids for, 1066
   testing for
      in MUO evaluation, 1171–1172
Inflammatory disease(s)
   noninfectious
      of CNS
         categorization of, 1158
Inherited neurologic disorders
   in dogs, 1223–1234. See also Neurologic disorders, inherited, canine
Intervertebral disk disease
   in cats
      as factor in prognosis after SCI, 1147–1148

L
Leukoencephalitis
   necrotizing
      signalment, neurologic signs, and histopathologic features of, 1168
Levetiracetam
   for SE in dogs, 1107–1109
Linear accelerator stereotactic radiosurgery
   in brain tumor management
      in dogs and cats, 1016
LMN. See Lower motor neuron (LMN)
Lower motor neuron (LMN)
   vs. UMN
      in clinical evaluation of patient following severe SCI, 1134
Lower motor neuron (LMN) tetraparesis
   acute, 1201–1222. See also Acute lower motor neuron (LMN) tetraparesis
Lysosomal storage diseases
   canine
      aging effects on, 1118–1119

M
Magnetic resonance imaging (MRI)
   in prognosis after SCI, 1148
Matrix metalloproteinases (MMPs)
   for neural injury and infection in small animals, 1192
MBP. See Myelin basic protein (MBP)
Meningitis
   corticosteroid-responsive
      glucocorticoids for, 1063
Meningoencephalitis
   necrotizing
   signalment, neurologic signs, and histopathologic features of, 1167–1168
Meningoencephalomyelitis
   granulomatous
   signalment, neurologic signs, and histopathologic features of, 1163–1166
Meningoencephalomyelitis of unknown origin (MUO), 1157–1185
   diagnostic evaluation of, 1168–1172
   brain biopsy in, 1171
   cross-sectional imaging in, 1169–1170
   CSF analysis in, 1171
   infectious disease testing in, 1171–1172
   glucocorticoids for, 1064
   granulomatous meningoencephalomyelitis, 1163–1166
   histopathologic features of, 1161–1163
   introduction, 1157–1159
   necrotizing encephalitis, 1166–1168
   neuroinflammation in, 1161–1163
   neurologic signs of, 1161–1163
   prognosis of, 1175–1176
   signalment of, 1163–1168
   treatment of, 1172–1175
Metabolism
   corticosteroid use effects on
   in small animals, 1061–1062
Microbial agents
   in infectious CNS disease
   testing for, 1194–1196
   bacteria, 1194–1195
   fungus, 1196
   protozoa, 1195
   rickettsia, 1196
   viruses, 1195
MMPs. See Matrix metalloproteinases (MMPs)
Monoclonal antibodies
   in brain tumor management
   in dogs and cats, 1027–1028
Movement disorders
   paroxysmal
   canine, 1091–1102
   inherited diseases, 1093–1099
   epileptoid cramping in Border Terriers, 1098
   episodic falling in Cavalier King Charles spaniels, 1093–1095
   episodic head tremor syndrome, 1098–1099
   PNKD in Chinooks, 1095
   Scottie cramp in Scottish Terriers, 1095–1098
   introduction, 1091–1093
   involuntary, 1100
   paroxysmal dyskinesia, 1099–1100
      in boxers, 1099
   phenobarbital-induced dyskinesia, 1100
Movement (continued)
phenobarbital-responsive paroxysmal dyskinesia, 1099–1100
sporadic reports, 1099–1100
MUO. See Meningoencephalomyelitis of unknown origin (MUO)
Muscle wasting
corticosteroid therapy and, 1068–1069
Mutation identification
in identifying underlying cause of inherited neurologic disorders in dogs, 1225
Myasthenia gravis
acquired acute fulminating, 1216–1218. See also Acquired acute fulminating
myasthenia gravis
glucocorticoids for, 1065–1066
Myelin basic protein (MBP)
for neural injury and infection in small animals, 1190
Myositis
immune-mediated
glucocorticoids for, 1064–1065

N
Necrotizing encephalitis
signalment, neurologic signs, and histopathologic features of, 1166–1168
Necrotizing leukoencephalitis
signalment, neurologic signs, and histopathologic features of, 1168
Necrotizing meningoencephalitis
signalment, neurologic signs, and histopathologic features of, 1167–1168
Neoplasia(s)
CNS
glucocorticoids for, 1065
Neural injury
biomarkers for, 1187–1199
cleaved tau, 1191
in diagnostic testing, 1188
GFAP, 1190–1191
growth factors, 1192
introduction, 1187–1188
limitations of, 1188–1192
MBP, 1190
MMPs, 1192
NSE, 1190
Neurodegeneration
ataxias without, 1085
Neurofilament heavy chain (NF-H)
phosphorylated
for neural injury and infection in small animals, 1191–1192
Neuroinflammation
histopathology of, 1161
in immune-mediated CNS disease, 1159–1161
in MUO, 1161–1163
overview of, 1159–1163
Neurologic disorders

inherited

- canine, 1223–1234
  - characteristics of, 1223–1224
  - DNA testing for, 1231–1233
  - identifying underlying cause of, 1224–1230
    - candidate gene analysis, 1228
    - genetic linkage analysis, 1226
    - genetic markers, 1225–1226
    - GWAS, 1226–1227
    - mutation identification, 1225
    - target resequencing, 1227–1228
    - whole genome sequencing, 1228–1229
    - whole transcriptome sequencing, 1229–1230
  - sources of data regarding, 1224

Neuron-specific enolase (NSE)

- for neural injury and infection in small animals, 1190

Neuronavigation, 1235–1248

- devices for
  - development of, 1236–1239
  - frameless systems, 1239
  - need for, 1235–1236
  - pointer-based frameless technique, 1240–1243. See also Pointer-based frameless neuronavigation technique
  - sources of error with, 1243–1244
  - uses of, 1244–1246
  - veterinary applications, 1244–1245
  - veterinary stereotaxy–related struggles and, 1239–1240

NF-H. See Neurofilament heavy chain (NF-H)

Niemann-Pick type C (NPC) disease

- feline
  - neuronal loss in
    - aging and, 1120–1121

Noninfectious inflammatory disease

- of CNS
  - categorization of, 1158

NPC disease. See Niemann-Pick type C (NPC) disease

NSE. See Neuron-specific enolase (NSE)

O

Oxygen and carbon dioxide

- in altered states of consciousness management, 1052–1054

P

Pain control

- glucocorticoids for, 1066–1067

Pain sensation

- detectable
  - as factor in prognosis after SCI, 1147
Paroxysmal dyskinesia
  in boxers, 1099
  phenobarbital-responsive
    canine, 1099–1100
Paroxysmal movement disorders
  canine, 1091–1102. See also Movement disorders, paroxysmal, canine
Paroxysmal nonkinesigenic dyskinesia (PNKD)
  in Chinooks, 1095
PCR. See Polymerase chain reaction (PCR)
Phenobarbital-induced dyskinesia
  canine, 1100
Phenobarbital-responsive paroxysmal dyskinesia
  canine, 1099–1100
Phosphorylated neurofilament heavy chain (NF-H)
  for neural injury and infection in small animals, 1191–1192
PNKD. See Paroxysmal nonkinesigenic dyskinesia (PNKD)
Pointer-based frameless neuronavigation technique, 1240–1243
  described, 1240
  identifiable fiducial markers, 1241–1242
  image space creation, 1242
  image tracker, 1243
  subject tracker, 1242–1243
  tomographic data set, 1240–1241
Polymerase chain reaction (PCR)–based techniques
  in infectious CNS disease testing, 1193–1194
  limitations of, 1194
Polyradiculoneuritis
  glucocorticoids for, 1065–1066
Protozoa
  in infectious CNS disease
    testing for, 1195
R
Radiosurgery
  stereotactic
    in brain tumor management
      in dogs and cats, 1015–1020. See also Stereotactic radiosurgery, in
        brain tumor management, in dogs and cats
Refractory status epilepticus (RSE)
  defined, 1104
  super
    defined, 1104
Rehabilitation
  after SCI
    role for, 1146
Respiratory dysfunction
  SCI and, 1137–1138
Rickettsia
  in infectious CNS disease
    testing for, 1196
RSE. See Refractory status epilepticus (RSE)
Schiff-Sherrington syndrome
  clinical evaluation of patient following severe SCI and, 1134–1135
SCI. See Spinal cord injury (SCI)
Scottie cramp
  in Scottish Terriers, 1095–1098
Scottish Terriers
  Scottie cramp in, 1095–1098
SE. See Status epilepticus (SE)
Seizure(s)
  acute repetitive
    defined, 1104
  cluster
    defined, 1104
    treatment of, 1109
  focal
    defined, 1104
  generalized
    defined, 1103
  terminology related to, 1103–1104
Sensory dysfunction
  SCI and, 1135–1136
Spinal cord function
  assessment of
    ancillary methods in, 1138–1142
    clinical scoring, 1138
    electrophysiologic measures, 1141–1142
    kinematics, 1139
    MRI advances, 1139–1140
Spinal cord injury (SCI)
  acute, 1131–1156
    introduction, 1131–1132
    treatment of
      cell transplantation in
        evidence for, 1142–1144
        in experimental canine models, 1144
        in experimental feline models, 1144–1145
      new pharmacologic interventions in, 1142
      standard of care with urinary retention management, 1145–1146
  blood pressure abnormalities following
    in dogs, 1137
  causes of, 1132–1133
  clinical cases with
    cell transplantation in, 1145
  early rehabilitation after
    role for, 1146
  experimental canine models of
    cell transplantation in, 1144
  prognosis following, 1147–1148
  respiratory dysfunction following, 1137–1138
Spinal (continued)
  sensory dysfunction following, 1135–1136
  severe
    clinical evaluation of patient following, 1133–1138
    normal locomotion, 1133
    sequential appearance of neurologic deficits after spinal cord damage, 1133–1134
    spinal shock and Schiff-Sherrington syndrome, 1134–1135
    UMN vs. LMN, 1134
  standards of care for, 1142–1146
  treatment of, 1142–1146
  urinary dysfunction following, 1136–1137
Spinal shock
  clinical evaluation of patient following severe SCI and, 1134–1135
Spinocerebellar degeneration
  canine, 1083–1085
SRSE. See Super refractory status epilepticus (SRSE)
Status epilepticus (SE), 1103–1112
  convulsive
    defined, 1104
  defined, 1103
  introduction, 1104–1105
  nonconvulsive
    defined, 1104
  refractory
    defined, 1104
    super
      defined, 1104
  treatment of, 1105–1109
    current and historical drug therapy in, 1106–1107
      in cats, 1107
      in dogs, 1107
      in humans, 1106–1107
    fosphenytoin in, 1109
    future possibilities in, 1110
    general considerations in, 1105–1106
    general standard of practice, 1107
    initial
      single-agent vs. combined therapy for, 1109
    levetiracetam in, 1108–1109
Stereotactic radiosurgery
  in brain tumor management
    in dogs and cats, 1015–1020
      CyberKnife stereotactic radiosurgery, 1017–1018
      described, 1019–1020
      Gamma Knife stereotactic radiosurgery, 1016–1017
      introduction/history, 1015
      linear accelerator stereotactic radiosurgery, 1016
      radiobiological considerations, 1018–1019
      technical aspects, 1015–1018
Super refractory status epilepticus (SRSE)
   defined, 1104

T
Target resequencing
   in identifying underlying cause of inherited neurologic disorders in dogs, 1227–1228
Tetraparesis
   acute LMN, 1201–1222. See also Acute lower motor neuron (LMN) tetraparesis
Tick paralysis, 1213–1216
   clinical signs of, 1214–1215
   diagnosis of, 1215
   introduction, 1213–1214
   pathophysiology of, 1214
   prevention of, 1216
   prognosis of, 1215–1216
   treatment of, 1215–1216
Transplantation
   cell. See Cell transplantation
Tumor(s)
   brain. See Brain tumors

U
UMN. See Upper motor neuron (UMN)
Upper motor neuron (UMN)
   vs. LMN
      in clinical evaluation of patient following severe SCI, 1134
Urinary dysfunction
   SCI and, 1136–1137

V
Vascular disorders
   in canine brain
      aging and, 1116–1117
Veterinary sternotomy
   struggles related to
      neuronavigation and, 1239–1240
Virus(es)
   in infectious CNS disease
      testing for, 1195
Vomiting
   corticosteroid therapy and, 1068

W
Whole genome sequencing, 1228–1229
Whole transcriptome sequencing
   in identifying underlying cause of inherited neurologic disorders in dogs, 1229–1230